1. Obesity is a major risk factor for various metabolic diseases, and the increase of obesity in recent decades has made it an urgent issue to develop effective strategies against this disorder.
2. Kynurenine (Kyn), a downstream catabolite of tryptophan (Trp), is upregulated in the plasma from certain subjects with obesity, which could be caused by the increased activity of indoleamine 2,3-dioxygenase 1 (IDO1).
3. This study found that mature adipocytes from white adipose tissue are critical for the metabolism of Kyn, and act as the primary source of increased circulating Kyn in subjects with obesity.
The article “Adipocyte-derived kynurenine promotes obesity and insulin resistance by activating the AhR/STAT3/IL-6 signaling” published in Nature Communications provides an interesting insight into how kynurenine (Kyn) can contribute to obesity and insulin resistance. The authors present evidence that suggests that Kyn is upregulated in certain individuals with obesity due to increased activity of indoleamine 2,3-dioxygenase 1 (IDO1). They also suggest that mature adipocytes from white adipose tissue are critical for the metabolism of Kyn, and act as the primary source of increased circulating Kyn in subjects with obesity.
The article appears to be well researched and reliable overall. The authors provide evidence to support their claims, such as citing studies on amino acid metabolism in adipocytes and related pathogenesis, as well as providing data from 735 human plasma samples collected from subjects with different BMI levels. Furthermore, they provide a detailed explanation on how Kyn can mediate a systemic effect on the development of obesity and insulin resistance via its interaction with aryl hydrocarbon receptor (AhR), Signal transducer and activator of transcription 3 (STAT3) and interleukin-6 (IL-6).
However, there are some potential biases or missing points worth considering when evaluating this article. For example, while the authors mention that supplementation of vitamin B6 can enhance Kyn catabolism and protect mice from HFD-induced obesity and insulin resistance, they do not discuss any potential risks associated with taking high doses of vitamin B6 supplements or other possible side effects. Additionally, while they cite studies on amino acid metabolism in adipocytes and related pathogenesis, they do not